New hope for kids with tough cancers: GAIA-102 trial launches

NCT ID NCT05608148

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and find the best dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood neoplasm chondrosarcoma Ewing sarcoma Ewing sarcoma/peripheral primitive neuroectodermal tumor germ cell tumor hepatoblastoma metastatic malignant neoplasm neuroblastoma osteosarcoma rhabdomyosarcoma undifferentiated (embryonal) sarcoma Wilms tumor 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kyushu University Hospital

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••